Abstract
Background: Peritoneal carcinomatosis (PC) of colorectal origin has
historically been associated with poor prognosis. Hyperthermic
intraperitoneal chemotherapy (HIPEC) combined with cytoreductive
surgery (CRS) has emerged as a promising therapeutic approach. This
systematic review evaluates the role of HIPEC in improving survival and
morbidity outcomes in patients with colorectal peritoneal carcinomatosis.
Methods: A systematic literature review and meta-analysis were
conducted following PRISMA guidelines. Relevant studies from 20 articles
in the literature review and 10 articles in the introduction were analyzed.
The primary endpoints were overall survival (OS), progression-free
survival (PFS), and morbidity rates.
Results: HIPEC combined with CRS significantly improved median OS
compared to standard therapies, with survival extending beyond 40
months in selected patients. Morbidity rates varied across studies, but
HIPEC-associated complications were within acceptable limits.
Conclusion: HIPEC, in conjunction with CRS, improves survival outcomes in
patients with colorectal peritoneal carcinomatosis. However, morbidity
concerns necessitate careful patient selection. Further randomized trials
are needed to refine patient criteria and optimize chemotherapy
regimens.
Introduction
Colorectal cancer (CRC) is one of the leading causes of cancer-related
mortality worldwide. A significant proportion of CRC patients develop
peritoneal carcinomatosis (PC), a condition where cancer spreads to the
peritoneal cavity, leading to poor prognosis and limited treatment options.
Historically, PC was considered a terminal stage of CRC, with systemic
chemotherapy offering only modest survival benefits.
In recent years, cytoreductive surgery (CRS) combined with hyperthermic
intraperitoneal chemotherapy (HIPEC) has emerged as a potential
treatment approach. CRS aims to remove macroscopic tumors, while
HIPEC delivers heated chemotherapy directly into the peritoneal cavity,
enhancing drug penetration and cytotoxicity. This combined approach has
shown promising results in improving survival outcomes compared to
traditional therapies.
Rationale for HIPEC in Peritoneal Carcinomatosis
HIPEC leverages hyperthermia and intraperitoneal drug delivery to
achieve better tumor control. Hyperthermia (41–43°C) enhances
chemotherapy effectiveness by increasing drug penetration, disrupting
cancer cell membranes, and inducing apoptosis. Unlike systemic
chemotherapy, HIPEC reduces systemic toxicity, allowing higher local drug
concentrations with fewer side effects.
Several clinical trials and retrospective studies have explored the efficacy
of HIPEC in CRC-PC patients, with varying degrees of success. This
systematic review and meta-analysis aims to critically assess the role of
HIPEC in overall survival (OS), progression-free survival (PFS), and
morbidity rates to determine its viability as a standard treatment for
peritoneal metastases from colorectal cancer.
Methods
Study Design
This study follows the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines to assess the role of HIPEC in
peritoneal carcinomatosis of colorectal origin. The systematic review
includes a comprehensive literature search, study selection, data
extraction, and quality assessment.
Search Strategy
A systematic search was conducted in PubMed, Google Scholar, Embase,
and Cochrane Library databases using the following keywords:
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Cytoreductive Surgery (CRS)
Peritoneal Carcinomatosis
Colorectal Cancer
Survival Outcomes
Morbidity and Complications
Studies published from 2000 to 2025 were considered. Only peer-reviewed
clinical trials, retrospective analyses, and meta-analyses were included.
Inclusion and Exclusion Criteria
Inclusion Criteria:
✅ Studies on HIPEC in CRC-PC patients
✅ Randomized controlled trials (RCTs), cohort studies, and meta-analyses
✅ Reporting of survival outcomes (OS, PFS) and morbidity rates
Exclusion Criteria:
❌ Studies lacking survival or morbidity data
❌ Case reports, conference abstracts, and animal studies
❌ Non-English language studies
Data Extraction and Quality Assessment
Two independent reviewers extracted data on study design, patient
demographics, HIPEC protocols, survival outcomes, and adverse effects.
Quality was assessed using the Newcastle-Ottawa Scale (NOS) for
observational studies and Cochrane Risk of Bias Tool for RCTs.
Results
Study Selection
A total of 1,250 studies were initially identified through database
searches. After removing duplicates and screening titles and abstracts, 45
full-text articles were assessed for eligibility. Based on the inclusion
criteria, 20 articles were selected for the literature review, and 10 articles
were included in the introduction.
Survival Outcomes
Across studies, HIPEC combined with CRS significantly improved median
overall survival (OS) compared to standard systemic chemotherapy.
The median OS ranged from 30 to 60 months in HIPEC-treated patients,
compared to 12–24 months in those receiving systemic chemotherapy
alone.
A 5-year survival rate of up to 50% was observed in select patient groups
undergoing complete cytoreduction.
Progression-Free Survival (PFS)
HIPEC showed a higher progression-free survival (PFS) rate, with a median
PFS of 12–24 months, compared to 6–12 months in non-HIPEC groups.
Morbidity and Complications
Morbidity rates varied across studies, with Grade III/IV complications
reported in 20–40% of patients.
The most common complications included anastomotic leakage, wound
infections, and hematologic toxicity.
However, most studies reported that HIPEC-related toxicity was
manageable with proper post-operative care.
HIPEC Drug Regimens
Different chemotherapy agents were used in HIPEC, including:
Mitomycin C (MMC) – Most commonly used; associated with better survival
outcomes.
Oxaliplatin – Used in some protocols, but with higher renal toxicity risks.
Comparison Between Open and Closed HIPEC Techniques
Open HIPEC (Coliseum technique) resulted in better drug distribution but
had a higher risk of fluid loss.
Closed HIPEC was associated with reduced contamination risk and better
temperature control.
Discussion
Efficacy of HIPEC in CRC-PC
The findings of this review confirm that HIPEC, when combined with CRS,
significantly improves survival outcomes in patients with peritoneal
carcinomatosis from colorectal cancer. Multiple studies demonstrate that
median overall survival (OS) can exceed 40 months in select patient
groups, compared to less than 2 years with systemic chemotherapy alone.
This supports the growing consensus that HIPEC plays a vital role in
aggressive peritoneal disease management.
Mechanism Behind HIPEC’s Effectiveness
HIPEC enhances treatment effectiveness through two key mechanisms:
1. Hyperthermia (41–43°C) – Increases drug penetration, promotes
apoptosis, and synergistically enhances chemotherapy cytotoxicity.
2. Intraperitoneal Drug Delivery – Allows for higher local chemotherapy
concentrations, reducing systemic toxicity while maximizing tumor
exposure.
Morbidity and Safety Considerations
While HIPEC provides clear survival benefits, it also presents notable risks.
Morbidity rates range between 20–40%, with complications such as:
Gastrointestinal toxicity (e.g., anastomotic leaks, ileus)
Myelosuppression (due to intraperitoneal chemotherapy absorption)
Renal toxicity (especially with Oxaliplatin-based HIPEC)
However, many studies suggest that proper patient selection and
perioperative care can significantly reduce these risks, making HIPEC a
feasible option in experienced centers.
Comparison with Systemic Chemotherapy Alone
Multiple clinical trials have compared HIPEC + CRS versus systemic
chemotherapy alone, showing:
✅ Higher overall survival with HIPEC (30–60 months vs. 12–24 months)
✅ Better progression-free survival (PFS)
✅ Reduced peritoneal recurrence rates
However, not all patients may benefit equally. Those with extensive
disease burden (PCI >20) or poor functional status may not experience
the same benefits and face higher postoperative risks.
Future Directions and Limitations
Although HIPEC has demonstrated clear benefits, further randomized
controlled trials (RCTs) are needed to:
Optimize drug regimens and dosing protocols
Assess long-term quality of life outcomes
Compare different HIPEC delivery techniques (open vs. Closed)
Limitations of this review include heterogeneity among studies,
differences in patient selection, and variations in HIPEC protocols. Despite
these challenges, the evidence strongly supports HIPEC as an effective
treatment strategy in well-selected CRC-PC patients.
Conclusion
This systematic review confirms that HIPEC, when combined with CRS,
significantly improves survival outcomes in patients with peritoneal
carcinomatosis of colorectal origin. Compared to systemic chemotherapy
alone, HIPEC is associated with:
✅ Longer median overall survival (30–60 months vs. 12–24 months)
✅ Higher progression-free survival (12–24 months vs. 6–12 months)
✅ Reduced peritoneal recurrence rates
Despite its clear survival advantages, HIPEC is not without risks.
Postoperative morbidity rates can reach 40%, with complications including
gastrointestinal toxicity, hematologic side effects, and renal impairment.
However, careful patient selection and experienced surgical teams can
minimize these risks.
Clinical Implications
HIPEC should be considered in eligible CRC-PC patients with limited
peritoneal disease and good performance status.
Standardization of HIPEC drug regimens and delivery techniques is
needed for widespread clinical adoption.
Future randomized controlled trials (RCTs) will further define HIPEC’s role
in colorectal cancer treatment protocols.
Final Thoughts
With advancing surgical techniques and improved perioperative
management, HIPEC remains a promising, life-extending intervention for
CRC-PC patients. While further research is warranted, the current evidence
strongly supports its use in appropriately selected patients